Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Adial Pharmaceuticals (ADIL) Net Cash Flow (2022 - 2024)

Adial Pharmaceuticals' Net Cash Flow history spans 3 years, with the latest figure at -$1.5 million for Q4 2024.

  • For Q4 2024, Net Cash Flow fell 195.31% year-over-year to -$1.5 million; the TTM value through Dec 2024 reached $923443.0, up 146.76%, while the annual FY2025 figure was $2.1 million, 130.73% up from the prior year.
  • Net Cash Flow for Q4 2024 was -$1.5 million at Adial Pharmaceuticals, down from $1.9 million in the prior quarter.
  • Across five years, Net Cash Flow topped out at $6.6 million in Q1 2022 and bottomed at -$3.5 million in Q2 2022.
  • The 3-year median for Net Cash Flow is -$1.0 million (2022), against an average of -$43294.1.
  • The largest YoY upside for Net Cash Flow was 336.76% in 2024 against a maximum downside of 195.31% in 2024.
  • A 3-year view of Net Cash Flow shows it stood at -$1.4 million in 2022, then surged by 208.61% to $1.5 million in 2023, then plummeted by 195.31% to -$1.5 million in 2024.
  • Per Business Quant, the three most recent readings for ADIL's Net Cash Flow are -$1.5 million (Q4 2024), $1.9 million (Q3 2024), and -$1.7 million (Q2 2024).